文献速递腹部介入CT

高危肝细胞癌患者的双低剂量双能肝脏CT:一项前瞻性随机单中心研究

Double Low-Dose Dual-Energy Liver CT in Patients at High-Risk of HCC: A Prospective, Randomized, Single-Center Study.
PubMed 文献 · Invest Radiol · 2020-01-01

该前瞻性随机单中心研究纳入67例体质量指数低于30的高危肝细胞癌患者,比较标准剂量组与双低剂量组(辐射和对比剂均目标降低30%)的病灶可见度和检出率。双低剂量组50 keV低单能谱图像在动脉期和门静脉期的病灶可见度均显著高于标准剂量组的混合迭代重建图像,而病灶检出能力无显著差异。

要点

  • 双低剂量组50 keV图像在动脉期和门静脉期的病灶可见度均显著高于标准剂量组的iDose图像。
  • 两组病灶检出能力无显著差异(品质因数标准剂量组0.63 vs 双低剂量组0.65,P=0.52)。
  • 双低剂量组主观图像噪声和对比度均优于标准剂量组,主动脉和门静脉对比噪声比更高。

关键影像表现/征象

  • 双低剂量组50 keV图像动脉期病灶可见度2.62(95%CI 2.31-2.93)vs 标准剂量组iDose图像2.02(95%CI 1.73-2.30),P=0.004。
  • 双低剂量组50 keV图像门静脉期病灶可见度2.39(95%CI 2.11-2.67)vs 标准剂量组iDose图像1.88(95%CI 1.67-2.10),P=0.005。
  • 双低剂量组50 keV图像在动脉期和门静脉期的主观图像噪声和对比度均优于标准剂量组iDose图像(P均<0.001)。
  • 双低剂量组主动脉和门静脉的对比噪声比均高于标准剂量组(P均<0.001)。
  • 两组动脉期和门静脉期的定量图像噪声无显著差异(P=0.4~0.5)。

诊断标准与关键数值

  • 双低剂量组CTDIvol为6.1±0.6 mGy,标准剂量组为8.8±1.7 mGy,双低剂量组显著更低(P<0.001)。
  • 双低剂量组对比剂用量为83.1±9.9 mL,标准剂量组为116.9±15.7 mL,双低剂量组显著更低(P<0.001)。
  • 病灶检出能力品质因数:标准剂量组0.63,双低剂量组0.65,两组无显著差异(P=0.52)。

临床应用与阅片要点

  • 对非肥胖高危肝细胞癌患者,可采用50 keV低单能谱图像在降低辐射和对比剂剂量的同时维持或提高病灶可见度。
  • 双低剂量组50 keV图像在动脉期和门静脉期的主观图像噪声和对比度均优于标准剂量组iDose图像(P均<0.001)。
  • 两组定量图像噪声在动脉期和门静脉期无显著差异(P=0.4~0.5),阅片时无需担心客观噪声增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The aim of this study was to investigate the clinical feasibility of the simultaneous reduction of radiation and contrast doses using spectral computed tomography (CT) in patients at high-risk for hepatocellular carcinoma.

MATERIALS AND METHODS: Between May 2017 and March 2018, this prospective study recruited participants at risk of hepatocellular carcinoma with body mass indexes less than 30 and randomly assigned them to either the standard-dose group or the double low-dose group, which targeted 30% reductions in both radiation and contrast media (NCT03045445). Lesion conspicuity as a primary endpoint and lesion detection rates were then compared between hybrid iterative reconstruction (iDose) images of standard-dose group and low monoenergetic (50 keV) images of double low-dose group. Qualitative and quantitative image noise and contrast were also compared between the 2 groups. Participants and reviewers were blinded for scan protocols and reconstruction algorithms. Lesion conspicuity was analyzed using generalized estimating equation analysis. Lesion detection was evaluated using weighted jackknife alternative free-response receiver operating characteristic analysis.

RESULTS: Sixty-seven participants (male-to-female ratio, 59:8; mean age, 64 ± 9 years) were analyzed. Compared with the standard-dose group (n = 32), significantly lower CTDIvol (8.8 ± 1.7 mGy vs 6.1 ± 0.6 mGy) and contrast media (116.9 ± 15.7 mL vs 83.1 ± 9.9 mL) were utilized in the double low-dose group (n = 35; P < 0.001). Comparative analysis demonstrated that lesion conspicuity was significantly higher on 50 keV images of double low-dose group than on iDose images of standard dose on both arterial (2.62 [95% confidence interval (CI), 2.31-2.93] vs 2.02 [95% CI, 1.73-2.30], respectively, P = 0.004) and portal venous phases (2.39 [95% CI, 2.11-2.67] vs 1.88 [95% CI, 1.67-2.10], respectively, P = 0.005). No differences in lesion detection capability were observed between the 2 groups (figure of merit: 0.63 in standard-dose group; 0.65, double low-dose group; P = 0.52). Fifty kiloelectronvolt images of double low-dose group showed better subjective image noise and contrast than iDose image of standard-dose group on arterial and portal venous phases (P < 0.001 for all). Contrast-to-noise ratio of the aorta and portal vein was also higher in double low-dose group than in standard-dose group (P < 0.001 for all), whereas there was no significant difference of quantitative image noise between the 2 groups on arterial and portal phases (P = 0.4~0.5).

CONCLUSIONS: Low monoenergetic spectral CT images (50 keV) can provide better focal liver lesion conspicuity than hybrid iterative reconstruction image of standard-dose CT in nonobese patients while using lower radiation and contrast media doses.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Yoon JH, Chang W, Lee ES, et al. Double Low-Dose Dual-Energy Liver CT in Patients at High-Risk of HCC: A Prospective, Randomized, Single-Center Study. Invest Radiol. 2020. PMID: 31917765. doi:10.1097/RLI.0000000000000643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。